500 related articles for article (PubMed ID: 27324636)
21. Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.
Katsanos S; Bistola V; Parissis JT
Expert Rev Clin Pharmacol; 2016 Apr; 9(4):513-523. PubMed ID: 26873036
[TBL] [Abstract][Full Text] [Related]
22. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Vilela-Martin JF
Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196
[TBL] [Abstract][Full Text] [Related]
23. The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update.
Nielsen PM; Grimm D; Wehland M; Simonsen U; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):9-18. PubMed ID: 28944989
[TBL] [Abstract][Full Text] [Related]
24. Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
Abumayyaleh M; El-Battrawy I; Behnes M; Borggrefe M; Akin I
Future Cardiol; 2020 Jul; 16(4):227-236. PubMed ID: 32186406
[TBL] [Abstract][Full Text] [Related]
25. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
Desai AS; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Chen F; Gong J; Rizkala AR; Brahimi A; Claggett B; Finn PV; Hartley LH; Liu J; Lefkowitz M; Shi V; Zile MR; Solomon SD
Eur Heart J; 2015 Aug; 36(30):1990-7. PubMed ID: 26022006
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
N Engl J Med; 2014 Sep; 371(11):993-1004. PubMed ID: 25176015
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact.
Buggey J; Mentz RJ; DeVore AD; Velazquez EJ
J Card Fail; 2015 Sep; 21(9):741-50. PubMed ID: 26209000
[TBL] [Abstract][Full Text] [Related]
28. Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies.
Tummala R; Bhadra R; Gupta A; Ghosh RK
J Cardiovasc Pharmacol; 2016 Sep; 68(3):183-90. PubMed ID: 27092662
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
Gori M; Volterrani M; Piepoli M; Senni M
Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
[TBL] [Abstract][Full Text] [Related]
30. Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
King JB; Bress AP; Reese AD; Munger MA
Pharmacotherapy; 2015 Sep; 35(9):823-37. PubMed ID: 26406774
[TBL] [Abstract][Full Text] [Related]
31. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
McMurray J; Packer M; Desai A; Gong J; Greenlaw N; Lefkowitz M; Rizkala A; Shi V; Rouleau J; Solomon S; Swedberg K; Zile MR; Andersen K; Arango JL; Arnold M; Bĕlohlávek J; Böhm M; Boytsov S; Burgess L; Cabrera W; Chen CH; Erglis A; Fu M; Gomez E; Gonzalez A; Hagege AA; Katova T; Kiatchoosakun S; Kim KS; Bayram E; Martinez F; Merkely B; Mendoza I; Mosterd A; Negrusz-Kawecka M; Peuhkurinen K; Ramires F; Refsgaard J; Senni M; Sibulo AS; Silva-Cardoso J; Squire I; Starling RC; Vinereanu D; Teerlink JR; Wong R;
Eur Heart J; 2015 Feb; 36(7):434-9. PubMed ID: 25416329
[TBL] [Abstract][Full Text] [Related]
32. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
Braunwald E
J Am Coll Cardiol; 2015 Mar; 65(10):1029-41. PubMed ID: 25766951
[TBL] [Abstract][Full Text] [Related]
33. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
Suematsu Y; Miura S; Goto M; Matsuo Y; Arimura T; Kuwano T; Imaizumi S; Iwata A; Yahiro E; Saku K
Eur J Heart Fail; 2016 Apr; 18(4):386-93. PubMed ID: 26749570
[TBL] [Abstract][Full Text] [Related]
34. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.
Bavishi C; Messerli FH; Kadosh B; Ruilope LM; Kario K
Eur Heart J; 2015 Aug; 36(30):1967-73. PubMed ID: 25898846
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.
Hua Y; Wang I; Liu B; Kelly DJ; Reid C; Liew D; Zhou Y; Wang BH
Future Cardiol; 2017 Mar; 13(2):103-115. PubMed ID: 27892684
[TBL] [Abstract][Full Text] [Related]
36. [ARNI, new abbreviation for a new class of treatment of heart failure].
Karimzadeh S; Mustafić H; Stampfli Andres T
Rev Med Suisse; 2017 Mar; 13(552):496-499. PubMed ID: 28714615
[TBL] [Abstract][Full Text] [Related]
37. Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost.
Manolis AS; Manolis TA; Manolis AA; Melita H
Am J Cardiovasc Drugs; 2019 Feb; 19(1):21-36. PubMed ID: 29926350
[TBL] [Abstract][Full Text] [Related]
38. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
Simpson J; Jhund PS; Silva Cardoso J; Martinez F; Mosterd A; Ramires F; Rizkala AR; Senni M; Squire I; Gong J; Lefkowitz MP; Shi VC; Desai AS; Rouleau JL; Swedberg K; Zile MR; McMurray JJV; Packer M; Solomon SD;
J Am Coll Cardiol; 2015 Nov; 66(19):2059-2071. PubMed ID: 26541915
[TBL] [Abstract][Full Text] [Related]
39. Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?
Bernardez-Pereira S; Ramires FJA; de Melo RFT; Pereira-Barretto AC
Cardiol Rev; 2018; 26(4):196-200. PubMed ID: 29369824
[TBL] [Abstract][Full Text] [Related]
40. [Neprilysin inhibition and chronic kidney disease].
Di Lullo L; Ronco C; Bellasi A; Cozzolino M; Floccari F; Barbera V; Verdesca S; Rivera R; De Pascalis A; Mudoni A; Santoro A
G Ital Nefrol; 2017 Sep; 34(5):102-112. PubMed ID: 28963831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
